TEL AVIV, Israel, July 19, 2010 (GLOBE NEWSWIRE) -- Mbeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.
Annual rates of skin cancer are increasing each year, representing a growing public concern. According to the American Academy of Dermatology (www.aad.org), more than two million cases of skin cancer are diagnosed in the United States each year. Recent research in the UK found the rate of men dying from the deadliest form of skin cancer has doubled over the past three decades. Current estimates are that one in five Americans will be diagnosed with skin cancer in their lifetime.
In the United States alone, the total direct cost associated with the treatment for non-melanoma skin cancer is estimated at $1.5 billion. The global market, including treatment for melanoma skin cancer, is estimated at several billion dollars.
Early detection is critical to survival, and can lead to almost a one hundred percent cure rate. However, the effectiveness of current cancer detection procedures is heavily dependent on the experience of the examiner, and errors in diagnosis can be fatal. Occasionally, cancers remained undetected, grow further and lead to lower chances of survival. Another disadvantage with current diagnostic methods is that they usually rely on a biopsy, the intrusive removal of tissue sample, to confirm the presence of cancerous tissue. Biopsies can be painful, leave scarring, and often cause unnecessary patient anxiety.
SCS is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment